Mirum Pharmaceuticals ( (MIRM) ) has released its Q1 earnings. Here is a breakdown of the information Mirum Pharmaceuticals presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for rare diseases affecting children and adults, with a portfolio that includes three approved medications and a promising pipeline of investigational therapies.
In the first quarter of 2025, Mirum Pharmaceuticals reported a total revenue of $111.6 million and announced an increase in its full-year revenue guidance to between $435 million and $450 million. The company also achieved significant milestones, including the FDA approval of the LIVMARLI oral tablet formulation and progress in its clinical studies.
Key financial highlights include a 71% increase in LIVMARLI net product sales compared to the first quarter of 2024, reaching $73.2 million. Additionally, Bile Acid Medicines saw a 47% growth in net product sales, totaling $38.4 million. The company also reported a strong balance sheet with $298.6 million in unrestricted cash, cash equivalents, and investments as of March 31, 2025.
Strategically, Mirum is advancing its pipeline with the VISTAS study for volixibat in primary sclerosing cholangitis expected to complete enrollment by the third quarter of 2025, and the LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions set to complete enrollment in 2026. The company is also planning to initiate a Phase 2 study for MRM-3379 in Fragile X Syndrome within the year.
Looking ahead, Mirum Pharmaceuticals remains committed to executing its strategic plans and achieving its financial guidance for 2025, while continuing to make progress across its commercial products and clinical pipeline.